Chart-Typ:
Zeitraum:
| From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? | LONDON (dpa-AFX) - The biotech sector continues to deliver headline-grabbing moves, with stocks surging to fresh highs and companies advancing pivotal trials, regulatory filings, and strategic... ► Artikel lesen |
| Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen |
| From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? | LONDON (dpa-AFX) - The biotech sector continues to deliver headline-grabbing moves, with stocks surging to fresh highs and companies advancing pivotal trials, regulatory filings, and strategic... ► Artikel lesen |
| Nuvation Bio to Participate in Upcoming Investor Conferences | Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief... ► Artikel lesen |
| Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer | Sustained durability of responses demonstrated in both TRUST-I and TRUST-II with additional follow-up time TKI-naïve patients in TRUST-I achieved a median progression-free survival of 44.6 months... ► Artikel lesen |
| Nuvation Bio To Present New Data on IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses | Presentations to include updated and additional Phase 2 clinical data for recently FDA-approved IBTROZI
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the... ► Artikel lesen |
| Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen |
| Nuvalent, Inc.: Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC | In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month... ► Artikel lesen |
| Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results | Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC
On track to report topline pivotal data for neladalkib in TKI... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ME THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.